Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

Leukemia. 2020 Apr;34(4):1197-1201. doi: 10.1038/s41375-019-0620-8. Epub 2019 Nov 12.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adaptor Proteins, Signal Transducing / antagonists & inhibitors
  • Adaptor Proteins, Signal Transducing / genetics
  • Adaptor Proteins, Signal Transducing / immunology
  • Adaptor Proteins, Signal Transducing / metabolism*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Clinical Trials as Topic
  • Drug Resistance, Neoplasm / drug effects*
  • Heterocyclic Compounds, 4 or More Rings / administration & dosage
  • Humans
  • Lenalidomide / administration & dosage
  • Leukocytes, Mononuclear / drug effects*
  • Leukocytes, Mononuclear / pathology
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / immunology
  • Multiple Myeloma / metabolism
  • Multiple Myeloma / pathology
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives
  • Tumor Cells, Cultured
  • Ubiquitin-Protein Ligases

Substances

  • Adaptor Proteins, Signal Transducing
  • CRBN protein, human
  • Heterocyclic Compounds, 4 or More Rings
  • iberdomide
  • Thalidomide
  • pomalidomide
  • Ubiquitin-Protein Ligases
  • Lenalidomide